AGOMELATINE IN CHILDREN AND ADOLESCENTS WITH MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER: 2-YEAR OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Falissard, B. [1 ]
Buitelaar, J. K. [2 ,3 ]
Fegert, J. M. [4 ]
Penelaud, P. F. [5 ]
Marx, U. [6 ]
Picarel-Blanchot, F. [7 ]
Arango, C. [8 ]
机构：
[1] Sante Mentale & Sante Publ, Ctr Rech Epidemiol & Sante Populat, INSERM, U018, Paris, France
[2] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Cognit Neurosci, Med Ctr, Nijmegen, Netherlands
[3] Karakter Child & Adolescent Psychiat Univ Ctr, Nijmegen, Netherlands
[4] Univ Hosp Ulm, Dept Child & Adolescent Psychiat Psychotherapy, Ulm, Germany
[5] Inst Rech Int Servier, Ctr Therapeut Innovat, Suresnes, France
[6] Servier Forsch & Pharma, Munich, Germany
[7] Global Med & Patient Affairs GMPA, Internal Med & Neuropsychiat, Suresnes, France
[8] Univ Complutense, Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth, IiSGM,Sch Med, Madrid, Spain
来源：
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | 2023年 / 57卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [41] Safety of long-term treatment with lurasidone in children and adolescents with bipolar depression: week 28 results of a 2-year open-label extension study
    Chang, K.
    DelBello, M.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Cucchiaro, J.
    Loebel, A.
    BIPOLAR DISORDERS, 2018, 20 : 66 - 66
  • [42] Combination cyclosporine(CsA)/methotrexate(MTX)for severe rheumatoid arthritis (RA): An open-label 2-year extension study.
    Yocum, DE
    Pincus, T
    Stein, CM
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S243 - S243
  • [43] Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder
    Emslie, Graham J.
    Yeung, Paul P.
    Kunz, Nadia R.
    CNS SPECTRUMS, 2007, 12 (03) : 223 - 233
  • [44] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
    Feagan, Brian G.
    Panes, Julian
    Ferrante, Marc
    Kaser, Arthur
    D'Haens, Geert R.
    Sandborn, William J.
    Louis, Edouard
    Neurath, Markus F.
    Franchimont, Denis
    Dewit, Olivier
    Seidler, Ursula
    Kim, Kyung-Jo
    Selinger, Christian
    Padula, Steven J.
    Herichova, Ivona
    Robinson, Anne M.
    Wallace, Kori
    Zhao, Jun
    Minocha, Mukul
    Othman, Ahmed A.
    Soaita, Adina
    Visvanathan, Sudha
    Hall, David B.
    Boecher, Wulf O.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10): : 671 - 680
  • [45] A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder
    Robinson, Donald S.
    Kajdasz, Daniel K.
    Gallipoli, Susan
    Whalen, Heidi
    Wamil, Art
    Reed, Carol R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (05) : 643 - 646
  • [46] Lurasidone for the treatment of major depressive disorder with mixed features: results of a 12-week open-label extension study
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S94 - S94
  • [47] LURASIDONE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH MIXED FEATURES: RESULTS OF A 12-WEEK OPEN-LABEL EXTENSION STUDY
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    Hopwood, M.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 145 - 146
  • [48] A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
    Richards, Cynthia
    Iosifescu, Dan V.
    Mago, Rajnish
    Sarkis, Elias
    Geibel, Brooke
    Dauphin, Matthew
    McIntyre, Roger S.
    Weisler, Richard
    Brawman-Mintzer, Olga
    Gu, Joan
    Madhoo, Manisha
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2018, 38 (04) : 336 - 343
  • [49] EFFICACY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Gonzalez, T.
    Xiao, J.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S90 - S91
  • [50] SAFETY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Sierka, D.
    Coleman, A.
    Gherardi, G.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S92 - S92
12345